Education

4/64 - 4/71 University of Tübingen, Germany - Diploma in Biochemistry

5/71 - 3/72 University of Münster, Germany, Institute of Biochemistry

4/72 - 9/75 University of Heidelberg, Germany - Ph.D. Molecular Genetics

Fellowships

1972-1975: Recipient of a fellowship for graduate studies at the Institute of Molecular Genetics (University of Heidelberg)

1975-1977: Recipient of a postdoctoral fellowship from the "Deutsche Forschungsgemeinschaft"

Professional Appointments

5/71 - 3/72 Assistant Biochemist - Institute of Biochemistry, University of Münster, Germany

10/75 - 9/77 Postdoctoral Fellow - University of California, Department of Biochemistry and Biophysics, San Francisco, U.S.A.

10/77 - 12/78 Assistant Research Biochemist - University of California, San Francisco, U.S.A.

1/79 - 10/84 Senior Scientist - Genentech, Inc., South San Francisco, U.S.A.

11/84 - 6/88 Staff Scientist - Genentech, Inc., South San Francisco, U.S.A.

12/88 - present Director - Department of Molecular Biology,

Max-Planck-Institut für Biochemie, Martinsried, Germany

1999 Managing Director - Max-Planck-Institut für Biochemie

07/2004 - present Visiting Scientist and Research Director of the Singapore Onco Genome Project, Centre for Molecular Medicine (CMM)), Agency for Science, Technology and Research (A*Star), Singapore

Science Advisory Boards

1991 - 1995 Science Advisory Board, Hagedorn Research Institute, Denmark

9/91 - 8/99 Board of Directors and Scientific Advisory Board, SUGEN, Inc.,

South San Francisco, U.S.A.

1992 - 1996 Advisory Board, Garching Innovation GmbH, Munich, Germany

1992 - 2000 Vice Chairman Advisory Board, Hans Knöll Institut, Jena, Germany

1995 - 2002 Science Advisory Board, The Wistar Institute, Philadelphia, USA

8/96 - present Founder and Vice Chairman of Academic Board - Cooperation Laboratory for Biological Signal Transduction Research, Second Military Medical University, Shanghai, China

11/96 - 2004 Chairman Advisory Board, Garching Innovation GmbH, Munich, Germany

07/97 – present Science Advisory Board, Bio^M AG, Martinsried, Germany

1/98 – present Board of Directors, Axxima Pharmaceuticals AG, Martinsried, Germany

1/99 – 12/1999 Co-Chairman Clinical Science Advisory Board, SUGEN/Pharmacia, U.S.A.

9/99 – 03/2003 Science Advisory Board, SUGEN/Pharmacia, U.S.A.

7/00 – present International Advisory Council (IAC), Agency of Science, Technology and Research (A*Star), Singapore

9/2001 Founder of U3 Pharma AG, Martinsried, Germany

2001 – present Chairman of the Board of Directors, U3 Pharma AG, Martinsried, Germany

2001 - 2003 Science Advisory Board, RZPD (German Resource Center for Genome Research), Berlin, Germany

2001 - present Science Advisory Board, Biomedicum, Helsinki, Finland

05/2003 – present One-North Resource Advisory Panel, JTC Corporation and Ministry for the Environment, Singapore

07/2003 – present Advisory Board, Boehringer-Ingelheim, Ingelheim; Germany

08/2003 – present International Panel for the Planning of a Research-Intensive University, Ministry of Education, Singapore

8/2003 - Board of Trustees, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

12/2003 – present Member of the Scientific Committee of Genoma Espana, Madrid, Spain

Memberships in Scientific Societies

Academia Europaea

The American Society for Cell Biology

Gesellschaft für Biochemie und Molekularbiologie e.V.

American Association for Cancer Research

International Union Against Cancer (UICC)

Deutsche Krebsgesellschaft

International Life Science Forum

American Association for the Advancement of Science (AAAS)

Elected Member of the Deutsche Akademie der Naturforscher Leopoldina

Elected Member of the American Academy of Arts & Sciences

Extramural Responsibilities

Editorial Board, Growth Factors

Editorial Board, Molecular Brain Research

Editorial Board, Receptors and Channels

Editorial Board, Journal of Cellular Physiology

Editorial Board, Cancer Genomics & Proteomics

Advisory Board, Molecules and Cells

Editorial Board, Molecular Cancer Research

Honors and Awards:

1987 Paul Langerhans Medal of the German Diabetes Society

1987 John W. Cline Memorial Lecturer (sponsored by the American Cancer Society), UCLA

1987 First Annual Ray A. and Robert L. Kroc Lecture, University of Massachusetts

1988 Berthold Medal of the German Society for Endocrinology

1990 Member of the European Molecular Biology Organization

1990: Mildred Scheel Memorial Lecture, Modern Trends in Human Leukemia Conference, Hamburg

1991 Prix Antoine Lacassagne from La Ligue Nationale Française Contre le Cancer, Paris, France

1996 11^th Annual Ray A. and Robert L. Kroc Lecture, Joslin Diabetes Center, Boston, U.S.A.

1996 Honorary Professor - Second Military Medical University, Shanghai, China

1996-98 Visiting Professor, Académie de Paris, Sorbonne, Paris, France

1997 Gold Medal and “XXII Lorenzini” Annual Lecture, Fondazione Giovanni Lorenzini,

Medical Science Foundation, Bari, Italy

1998 German Cancer Prize of the German Cancer Society, Frankfurt, Germany

1999 Ludwig Heilmeyer Lecture, The International Society of Gastroenterological Carcinogenesis, Ulm

2000 Honorary Professor, University of Tübingen, Germany

2000 Bruce F. Cain Memorial Award, American Association for Cancer Research

2000 Elected Member of the Deutsche Akademie der Naturforscher Leopoldina

2001 Busenfreund, a prize awarded by mamazone – women and science against breast cancer e.V.

2001 Robert-Koch Prize of the Robert-Koch-Foundation

2001 International Fellow, Garvan Institute of Cancer Research, Sydney, Australia

2002 Virchow Lecture, University of Würzburg, Germany

2002 IJC-Meyenburg Lecture, University of Heidelberg, Germany

2003 King Faisal International Prize for Medicine, King Faisal Foundation, Saudi Arabia

2003 Meyer-Schwickerath Lecture, Society of Medical Science, Essen, Germany

2003 Honorary Member of The World Innovation Foundation

2005 Warburg Medal, Society of Biological Chemistry, Germany

2005 Elected Member of the American Academy of Arts & Sciences

2005 European BioBusiness Leadership Award , USC Marshall School of Business, U.S.A.

Major Scientific Achievements

Insulin

First cloning of preproinsulin cDNA leading subsequently to the development of the first gene-technology-based therapeutic protein product by Genentech, Inc. and Eli Lilly Corp. "Humulin"

Ullrich, A., Shine, J., Chirgwin, J., Pictet, R., Tischer, E., Rutter, W.J., and Goodman, H.M. (1977) Rat insulin genes: Construction of plasmids containing the coding sequences. Science 196, 1313-1319.

Sures, I., Goeddel, D., Gray, A., and Ullrich, A. (1980) Nucleotide sequence of human preproinsulin complementary DNA. Science 208, 57-59.

Growth Factors

Elucidation of primary structures, by cDNA cloning, of the precursor proteins for EGF, NGF IGF-1, and IGF-2.

Gray, A., Dull, T.J., and Ullrich, A. (1983) Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. Nature 303, 722-725.

Ullrich, A., Gray, A., Berman, C., and Dull, T.J. (1983) Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 303, 821-825.

Ullrich, A., Berman, C.H., Dull, T.J., Gray, A., and Lee, J.M. (1984) Isolation of the human insulin-like growth factor I gene using a single synthetic DNA probe. EMBO Journal 3, 361-364.

Dull, T.J., Gray, A., Hayflick, J.S., and Ullrich, A. (1984) Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature 310, 777-781.

Growth Factor Receptor Tyrosine Kinases

Cloning and primary structure elucidation of the first signal transducing cell surface protein, the EGF-receptor. First complete characterization of a protooncogene (c-erbB) product with known biological function. Discovery of EGFR gene amplification in cancer cells.

Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, T.A., Schlessinger, J., Downward, J., Mayes, E.L.V., Whittle, N., Waterfield, M.D., and Seeburg, P.H. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.

Cloning and characterization of receptors for insulin (IR))], PDGF, IGF-1, CSF-1 and SCF. Elucidation of oncogenic mutations in CSF-1- and SCF (kit) receptors. All but the IR currently serve as targets for cancer drug development.

Ullrich, A., Bell, J.R., Chen, E.Y., Herrera, R., Petruzzelli, L.M., Dull, T.J., Gray, A., Coussens, L., Liao, Y-C., Tsubokawa, M., Mason, A., Seeburg, P.H., Grunfeld, C., Rosen, O.M., and Ramachandran, J. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761.

Yarden, Y., Escobedo, J.A., Kuang, W-J., Yang-Feng, T.L., Daniel, T.O., Tremble, P.M., Chen, E.Y., Ando, M.E., Harkins, R.A., Francke, U., Fried, V.A., Ullrich, A., and Williams, L.T. (1986) Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor

receptors. Nature 323, 226-232.

Ullrich, A., Gray, A., Tam, A.W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., Jacobs, S., Francke, U., Ramachandran, J., and Fujita-Yamaguchi, Y. (1986) Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO Journal 5, 2503-2512.

Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R.L., Isacke, C.M., Verma, I.M., and Ullrich, A. (1986) Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature 320, 277-280.

Yarden, Y., Kuang, W-J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T.J., Schlessinger, J., Francke, U., and Ullrich, A. (1987) Human proto-oncogene c-kit: A new cell surface receptor-tyrosine kinase for an unidentified ligand. EMBO Journal. 6, 3341-3351.

Target-specific Cancer Therapy

Discovery of the putative growth factor receptor HER2/neu and demonstration of its major role in mammary and ovarian carcinoma progression. Development of HER/neu-specific monoclonal antibody 4D5, which was subsequently developed to the first gene-based , target-specific anti-oncogene cancer therapeutic -Herceptin- (Genentech Inc. / Hoffmann-La Roche) and is available to breast cancer patients since 11/1998.

In 2005 results of a multi-center trial (HERA) which were reported at ASCO demonstrated a major benefit for HER2 positive breast cancer patients in adjuvant therapy preventing tumor recurrence in 46% of the probands.

Coussens, L., Yang-Feng, T.L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139.

Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.

Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.

Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M., and Ullrich, A. (1989) p185^HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172.

Patents:

Method of Treating Tumor Cells by Inhibiting Growth Factor Receptor Function; Hudziak, R., Shepard, H.M., and Ullrich, A. (WO 89/06692; Jul 27, 1989)

In Vivo Tumor Detection Assay

(U.S. Patent 5,720,937; Feb 24, 1998)

Hudziak, R., Ullrich, A., Fendly, B.M. (1998)

HER2 Extracellular Domain

(EP 0 474 727 B1, Jul 23, 1997, U.S. Patents 6,015,567; Jan 18, 2000, 6,333,169 B1; Dec 25, 2001)

Hudziak, R., Shepard, H.M., Ullrich, A.

Monoclonal Antibodies Directed to the HER2 Receptor

(U.S. Patents 5,677,171; Oct 14, 1997, 5,720,954, Feb 24, 1998, 5,725,856; March 10, 1998, 5,770,195; Jun 23, 1998, 5,772,997; Jun 30, 1998, 6,165,464, Dec 26, 2000, 6,387,371 B1, May 14, 2002, 6,399,063 B1; Jun 4, 2002)

Hudziak, R., Shepard, R, M., Ullrich, A., Fendly, B.M.

Angiogenesis and Anti-Angiogenesis Therapy

Identification of Flk-1/VEGFR2 as the critical receptor for the development of the vascular system and for tumor angiogenesis resulting in the development of the target-specific (Flk-1/VEGFR2) anti-angiogenic drug (SU5416) and the multi-targeted drugs SU6668 and SU11248 by SUGEN, Inc. for the treatment of various cancer indications. SU11248 (SUTENT) was submitted in July 2005 (Pfizer) to the FDA for approval for the treatment of Gleevec-resistant Gastrointestinal Stromal Tumors (GIST). Phase III trials are ongoing for therapy of renal cell carcinoma and other indications.

SU11248 is the first “designed” multi-targeted cancer drug (Pfizer)

Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Møller, N.P.H., Risau, W., and Ullrich, A. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846.

Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.

Millauer, B., Longhi, M.P., Plate, K.H.,~~Fong, T.A.T.,~~ Shawver, L.K., Risau, W., Ullrich, A., and Strawn~~Sun~~, L.M. (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620.

Strawn, L.M., ~~, Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X.Y., Risau, W., Ullrich, A., Hirth, K.P. and~~ McMahon, G., App, H., Schreck, R., Kuchler, W.R., Longhi, M.P., Hui, T.H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Kéri, G., Orfi,, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K.P. and Shawver, L.K. (1996) Flk-1 as a Target for Tumor Growth Inhibition. Cancer Res. 56, 3540-3545.

Fong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X.Y., Risau, W., Ullrich, A., Hirth, K.P., and McMahon, G. (1999) SU5416 is a potent and selective~~Potent and Selective~~ Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) that Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res ~~Research~~ 59 (1), 99-106.

Laird, A.D., Vajkoczy, P., Shawver, L.K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S.R., Blake, R.A., Fong, A.T., Strawn, L.M., Sun, L., Tang, C., Hawtin, R., Tang, F., Hirth, K.P., McMahon, G., and Cherrington, J. (2000) SU6668 is a potent Anti-Angiogenic and Anti-Tumor Agent which Induces Regression of Established Tumors. Cancer Res. 60 (15), 4152-4160.

Patents:

Flk-1 Is a Receptor for Vascular Endothelial Growth Factor

(U.S. Patent 5,851,999; Dec 22, 1998, EP 0 669 978 B1; Apr 23, 2003))

Ullrich, A., Risau, W., Millauer, B. (1998)

Use of Organic Compounds for the Inhibition of Flk-1 Mediated Vasculogenesis and Angiogenesis

(U.S. Patent 6,177401 B1; Jan 23, 2001)

Ullrich, A., Risau, W., Millauer, B.

Cellular Signaling Network

Discovery and characterization of the G-protein-coupled EGF Receptor Transactivation pathway in normal and cancer cells. Demonstration that physiological factors like LPA, Angiotensin II, Endothelin and others maybe involved in cancer progression.

Daub, H., Weiss, F.U., Wallasch, C. and Ullrich, A. (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560.

Zwick, E., Daub, H., Aoki, N., Yamaguchi-Aoki, Y., Tinhofer, I., Maly, K. and Ullrich, A. (1997) Critical Role of Calcium-dependent Epidermal Growth Factor Receptor Transactivation in PC12 Cell Membrane Depolarization and Bradykinin Signaling. J.Biol.Chem. 272, 24767-24770

Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R. Wallasch, C. and Ullrich, A (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 402, 884-888.

Gschwind, A., Hart, S., Fischer, O.M., and Ullrich, A. (2003) TACE Cleavage of Proamphiregulin Regulates GPCR-induced Proliferation and Motility of Cancer Cells. EMBO Journal. 22 (10), 2411-2421.

Patents:

Use of Proteinase Inhibitor in Order to Inhibit the Cleavage of Growth Factor Precursor

(Australian Patent 779 298; May 12, 2005, WO 01/12182 A1)

Ullrich, A., Prenzel, N., Daub, H., Zwick-Wallasch, E. (1999)

Use of EGFR Transactivation Inhibitors in Human Cancer

(WO 03/075947 A1, PCT/EP 03/02361)

Ullrich, A., Schäfer, B., Fischer, O., Gschwind, A., Leserer, M. (2003)

Inhibition of TACE or Amphiregulin for the Modulation of EGF Receptor Signal Transactivation

(WO 2004/073734 A1, PCT/EP 2004/001691)

Ullrich, A., Gschwind, A., Hart, S.

Discovery of the FGF Receptor 4 Germ Line 388Arg Allele

Demonstration of the prognostic significance of this SNP for breast- and colon cancer patients. Establishment of FGFR4 as intervention target for cancer therapy.

Bange, J., Prechtel, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., Wang, H., Imyanitov, E., Häring, H.U., Knyazev, P., Iacobelli, S., Höfler, H. and Ullrich, A. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Research 62, 840-847.

Streit, S., Bange, J., Fichtner, A., Ihrler, S., Issing, W., and Ullrich, A. (2004) Involvement of the FGFR4 Arg388 Allele in Head and Neck Squamous Cell Carcinoma. Int. J. Cancer 111, 213-217.

Patent:

Use of Inhibitors for the Treatment of Disorders Related to RTK Hyperfunction, Especially Cancer

(U.S. Patent 6,770,742 B1; Aug 3, 2004, EP 9900405, AU 756378 B2)

Ullrich, A., Bange, J., Knyazev, P.

Citation Ranking

According to Science Watch (Vol. 14, No. 5, 2003) A. Ullrich ranks internationally at position 9 of most cited scientists during the 1983-2002 period with 58.395 citations. He is the most cited German and 3^rd ranked European scientist during this period.

PATENTS

UCSF

Method for Producing Recombinant Bacterial Plasmids Containing the Coding Sequences of Higher Organisms

(U.S. Patent 4,440,859; Apr. 3, 1984)

Rutter, W.J., Goodman, M., Ullrich, A., Shine, J., Chirgwin, J., Pictet, R.

Recombinant Bacterial Plasmids Containing the Coding Sequences of Insulin Genes

(U.S. Patent 4,652,525; Mar 24, 1987)

Rutter, W.J., Pictet, R., Chirgwin, J., Goodman, H., Ullrich, A., Shine, J

Genentech

Insulin Receptor

(U.S. Patent 4,761,371; Aug 2, 1988)

Bell, J., Ramachandran, J., Ullrich, A.

Method of Detecting Truncated Epidermal Growth Factor Receptors

(U.S. Patent 4,933,294; Jun 12, 1990)

Waterfield, M.D., Schlessinger, J., Ullrich, A.

Receptor for Efficient Determination of Ligands and their Antagonists or Agonists

(U.S. Patent 5,030,576; Jul 9, 1991)

Dull, T., Riedel, H., Ullrich,A.

Human Nerve Growth Factor by Recombinant Technology

(U.S. Patent 5,169,762; Dec 8, 1992; 5,288,622; Feb 22, 1994)

Gray, A., Ullrich, A.

Improvements Relating to Growth Factors

(EP 0 171 407 B1; Nov 18, 1993)

Waterfield, M.D., Schlessinger, J., Ullrich, A.

Hybrid Receptors, Nucleic Acid Encoding them, their Preparation, and their Use in Determination of Ligands and their Antagonists and Agonists

(EP 0 244 221 B1, Jun 26, 1996)

Dull, T., Riedel, H., Ullrich,A.

Monoclonal Antibodies Directed to the HER2 Receptor

Hudziak, R., Shepard, R, M., Ullrich, A., Fendly, B.M.

HER2 Extracellular Domain

(EP 0 474 727 B1, Jul 23, 1997, U.S. Patents 6,015,567; Jan 18, 2000, 6,333,169 B1; Dec 25, 2001)

Hudziak, R., Shepard, H.M., Ullrich, A.

In Vivo Tumor Detection Assay

(U.S. Patent 5,720,937; Feb 24, 1998)

Hudziak, R., Ullrich, A., Fendly, B.M. (1998)

Preparation of Human IGF and EGF via Recombinant DNA Technology

(U.S. Patents 6,331,414 B1; Dec 18, 2001, 6,331,609 B1; Dec 18, 2001)

Lee, J., Ullrich, A.

A Method for Culturing Recombinant Cells

(U.S. Patents 6,235,498 B1; May 22, 2001; 6,399,331 B2; Jun 4, 2002)

Mather, J.P., Ullrich, A.

Method of Treating Tumor Cells by Inhibiting Growth Factor Receptor Function

(WO 89/06692; Jul 27, 1989)

Hudziak, R., Shepard, H.M., Ullrich, A.

Max-Planck-Institut für Biochemie

Verfahren zur Diagnose von nicht-Insulin-abhängigem Diabetes mellitus

(DE 41 14 365 C2)

Process for Diagnosing Non-Insulin-Dependent Diabetes Mellitus

(U.S. Patent 5,719,022; Feb 17, 1998))

Ullrich, A., Seedorf, L., Häring, H.U.,

Extracellular Signal-Regulated Kinase, Sequences, and Methods of Production and Use (Australian Patent 682506; U.S. Patents 5,459,036; Oct 17, 1995, 6,579, 972B1; Jun 17, 2003)

Ullrich, A., Lechner, C., Møller. N.P.H.

PTP-S31: A Novel Protein Tyrosine Phosphatase

(U.S. Patents 5,585,233; Dec 17, 1996, 6,492,495 B1, Dec 10, 2002)

Ullrich, A. , Møller, N.P.H., Møller, K.,

Verfahren zur Aktivitätsbestimmung von Phosphotyrosinphosphatasen und zur Identifizierung von Effektoren davon

(German Patent DE 44 39 662 C2, Oct 2, 1997, EP 0 791 072 B1; May 17, 2000)

Ullrich, A., Böhmer, F.D., Böhmer, S.A., Obermeier, A.

Recombinant DNA Encoding CCK-2, a Receptor Tyrosine Kinase

(U.S. Patent 5,677,144, Oct 14, 1997, EP 0 090 315 B1; May 25, 2005)

Ullrich, A., Alves, F.

Treatment of Platelet Derived Growth Factor Related Disorders Such as Cancer

(U.S. Patents 5,700,822; Dec. 23, 1997, 5,700,823; Dec 23, 1997, 5,932,602; Aug 3, 1999, 5,958,959; Sep 28, 1999, 5,990,141; Nov 23, 1999, 6,331,555 B1; Dec 18, 2001, EP 0 804 191 B1; May 17, 2000)

Ullrich, A., Lammers, R., Hirth, K.P., Pruess Schwarz, D., Mann, E., Shawver, L.K

Flk-1 Is a Receptor for Vascular Endothelial Growth Factor

(U.S. Patent 5,851,999; Dec 22, 1998, EP 0 669 978 B1; Apr 23, 2003))

Ullrich, A., Risau, W., Millauer, B. (1998)

Methods for Identifying Modulators of Insulin Receptor Phosphorylation

(U.S. Patent 5,856,111; Jan 5, 1999)

Ullrich, A., Hoppe, E., Møller, N.P.H. (1999)

Receptor-Type Phosphotyrosine Phosphatase-Kappa

(US Patent 5,856,162; Jan 5, 1999)

Schlessinger J., Sap, J.M., Ullrich, A., Vogel, W., Fuchs, M

Treatment of Diabetes Mellitus and Insulin Receptor Signal Transduction

(U.S. Patent 5,861,266; Jan 19, 1999)

Ullrich, A., Lammers, R., Kharitonenkov, A., Sap, J.M., Schlessinger, J.

Diagnosis and Treatment of TKA-1 Related Disorders

(U.S. Patents 5,895,813; Apr 20, 1999, 5,945,523; Aug 31, 1999)

Ullrich, A., Seedorf, K.

Method for the Determination of the Activity of Specific Phosphotyrosine Phosphatases and Specific Effectors thereof in Intact Cells

(U.S. Patent 5,958,719; Sep 28, 1999)

Ullrich, A., Böhmer, F.D., Böhmer S.A., Obermeier, A.

DNA Encoding MCK-10, A Novel Receptor Tyrosine Kinase

(U.S. Patent 6,051,397; Apr 18, 2000)

Ullrich, A., Alves, F.

Prognosis of PTP LAR Related Diseases

(EP 1 169 054 B1; Apr 6, 2000)

Products and Methods for Treating PTP LAR Related Diseases

(WO 00/061180 A3)

Ullrich, A., Müller, T.

MDK 1, A Novel Receptor Tyrosine Kinase

(U.S. Patent 6,300,482 B1; Oct 9, 2001)

Ullrich, A., Millauer, B., Ciossek, T.,

Megakaryotic Protein Tyrosine Kinases

(U.S. Patents 6,326,469 B1; Dec 4, 2001, 6,908,984 B2; Jun 21, 2005)

Ullrich, A., Gishitzky, M., Sures, I.

SIRP Proteins and Uses Thereof

(U.S. Patent 6,541,615 B1; Apr 1, 2003)

Ullrich, A., Kharitonenkov, A., Chen, Z.

PTP-D Subfamily of Protein Tyrosine Phosphatases

(EP 0 654 083 B1; Apr 16, 2003, WO 94/03611 A2, A3,)

Ullrich, A., Møller, N.P.H, Møller K.B.

Use of Inhibitors for the Treatment of Disorders Related to RTK Hyperfunction, Especially Cancer

(U.S. Patent 6,770,742 B1; Aug 3, 2004, EP 9900405, AU 756378 B2)

Ullrich, A., Bange, J., Knyazev, P.

Nucleic Acid Encoding CLK2 Protein Kinases

(U.S. Patent 6,797,513 B2; Sep 28, 2004))

Ullrich, A., Nayler, O.

Use of Proteinase Inhibitor in Order to Inhibit the Cleavage of Growth Factor Precursor (Australian Patent 779 298; May 12, 2005, WO 01/12182 A1)

Ullrich, A., Prenzel, N., Daub, H., Zwick-Wallasch, E. (1999)

Patent Applications:

Mutated Growth Factor Receptor as Medicament and its Use for Treating Cancer

(WO 1993/05148 A1, PCT/EP 92/02058)

Ullrich, A., Redemann, N.

Screening Assays for Compounds

(WO 96/40276, PCT/US95/08332)

Ullrich, A., App, H., Hirth, P., Tsai, J.

Novel PTP20, PCP-2, BDP1, CLK and SIRP Proteins and Related Products and Methods

(WO 97/48723, PCTIB97/00946)

Ullrich, A., Kharitonenkov, A., Aoki, N., Wang, H.Y., Chen, Z., Kim, Y.W.

Pyruvate-Kinase as a Novel Target Molecule

(WO 02/095063 A1, PCT/EP 02/05684)

Ullrich, A., Stetak, A., Keri, G.

Method for Identifying Functional Nucleic Acids

(WO 2002/063037 A3, PCT/EP 2002/001073)

Ullrich, A., Abraham, R.

PYK2 Phosphorylation by HER3 Induces Tumor Invasion

(WO 02/060470 A1, PCT/EP 02/01015)

Ullrich, A., Htun van der Horst, E.

Inhibitors HER3 Antibodies

(WO 02/013602 A1, PCT/EP 02/08938)

Ullrich, A., Htun van der der Horst, E.

Use of EGFR Transactivation Inhibitors in Human Cancer

(WO 03/075947 A1, PCT/EP 03/02361)

Ullrich, A., Schäfer, B., Fischer, O., Gschwind, A., Leserer, M. (2003)

Inhibition of TACE or Amphiregulin for the Modulation of EGF Receptor Signal Transactivation

(WO 2004/073734 A1, PCT/EP 2004/001691)

Ullrich, A., Gschwind, A., Hart, S.

Diagnose und Prävention von Krebszellinvasion/Diagnosis and Prevention of Cancer Cell Invasion

(WO 2004/008147 A3, PCT/EP2003/007786)

Ullrich, A., Knyazev, P., Knyazeva, T., Cheburkin, Y., Vajkoczy, P.

Inhibition of Stress-Induced Ligand-Dependent EGFR Activation

(WO 2005/4893 A1, A2, A3, PCT/EP2004/007329)

Ullrich, A., Fischer, O.

Spezifisches Targeting von pharmazeutischen Zusammensetzungen umfassend ein Trägerprotein mit mindestens einem Aminosäureanalogum

(DE 102 55 132 A1; Jul 15, 2004)

Budisa, N., Rubini, M., Huber, R., Knyazev, P., Ullrich, A., Neuefeind, T. (2002)